ArticlePLoS medicine2007

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

Patricia C Galipeau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.